Estimated risk of invasive breast cancer in postmenopausal women with and without family history of the disease

2011 ◽  
Vol 18 (5) ◽  
pp. 515-520 ◽  
Author(s):  
Angelina Sontag ◽  
Lawrence Wickerham ◽  
Xiao Ni ◽  
Beth D. Mitchell ◽  
Cameron Helt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Postmenopausal Women ◽  
Invasive Breast Cancer ◽  
History Of ◽  
Estimated Risk

scholarly journals Family history of later-onset breast cancer, breast healthy behavior and invasive breast cancer among postmenopausal women: a cohort study

2010 ◽  
Vol 12 (5) ◽  
Author(s):  
Robert Gramling ◽  
Timothy L Lash ◽  
Kenneth J Rothman ◽  
Howard J Cabral ◽  
Rebecca Silliman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Family History ◽  
Postmenopausal Women ◽  
Invasive Breast Cancer ◽  
Healthy Behavior ◽  
Cancer Breast ◽  
History Of

Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses' Health Study (United States)

1995 ◽  
Vol 6 (3) ◽  
pp. 217-224 ◽  
Author(s):  
Susan E. Hankinson ◽  
Graham A. Colditz ◽  
David J. Hunter ◽  
JoAnn E. Manson ◽  
Walter C. Willett ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Family History ◽  
Postmenopausal Women ◽  
Reproductive Factors ◽  
Health Study ◽  
History Of

Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer

2008 ◽  
Vol 14 (1) ◽  
pp. 6-12 ◽  
Author(s):  
Trevor J Powles ◽  
Anthony Howell ◽  
D Gareth Evans ◽  
Eugene V Mccloskey ◽  
Sue Ashley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adverse Event ◽  
Family History ◽  
Postmenopausal Women ◽  
Breast Density ◽  
Red Clover ◽  
Mineral Density ◽  
Adverse Event Profile ◽  
Healthy Women ◽  
History Of

Objective To assess the safety and tolerability of a standardized 40 mg red clover isoflavone dietary supplement (Promensil®, Novogen) in women with a family history of breast cancer to evaluate the feasibility of using the supplement for prevention of breast cancer in healthy women. Study design Healthy women aged 35–70 years (n = 401) with at least one first-degree relative with breast cancer received red clover isoflavones or placebo for three years in a randomized, double-blind, placebo-controlled pilot trial. Participants were assessed clinically and blood samples taken for biochemical analysis every six months. In addition, study participants underwent mammography, bone density and transvaginal ultrasound (postmenopausal women only) once per year. Results No significant differences in breast density, endometrial thickness, serum cholesterol, follicle stimulating hormone levels and bone mineral density were detected between those taking red clover isoflavones and placebo. In postmenopausal women, some significant differences in bone marker levels were seen between active and placebo groups, at six months and at 12 months. The adverse event profile was similar across all red clover isoflavone and placebo groups. Conclusion This three-year study supports the growing body of evidence that treatment with red clover isoflavones is safe and well tolerated in healthy women. Supplements containing red clover isoflavones did not adversely affect breast density, skeletal strength or cardiovascular status. In postmenopausal women, endometrial status was not adversely affected. The adverse event profile was similar between red clover isoflavones, and placebo and endocrine status did not differ.

Identifying women at high risk for invasive breast cancer at the time of screening mammography.

2013 ◽  
Vol 31 (26_suppl) ◽  
pp. 6-6
Author(s):  
Mary Lorraine Lopresti ◽  
Kathryn L. Edmiston ◽  
Rahul Sood ◽  
Shrinkala Khanna
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
High Risk ◽  
Invasive Breast Cancer ◽  
Screening Mammography ◽  
Environmental Data ◽  
Gail Model ◽  
Model Risk ◽  
Increased Risk ◽  
History Of

6 Background: Most mammography centers collect reproductive, family, and environmental data on patients presenting for screening mammograms. These data, if entered into a Gail Model Risk Assessment Tool, can help identify those patients at increased risk. These patients can then be referred to high-risk centers that will focus on risk-reduction strategies. Methods: This study is an observational prospective cohort of 1,000 women presenting for mammographic screening or diagnostic evaluation at mammography clinics affiliated with a single institution. Women at the time of their mammogram were asked to fill out a standard intake sheet by the institutional clinic. These data sheets were gathered and Gail model risk scores were calculated. Women with a 5-year risk of invasive breast cancer of 1.7% or greater were identified. Patients with a history of breast cancer or who underwent diagnostic mammography were excluded. A high risk subgroup was identified and risk factors were analyzed. Women at particularly high risk ( ≥ 3.4% or double the 5-year risk) were analyzed separately. Results: Of 1,000 women screened, 366 had ≥ 1.7% 5-year risk of invasive breast cancer. 26% (96) of these women were under 60 years old while 74% (270) were ≥ 60 years old. Among the latter group, 19.6% (53) were found to have ≥ 3.4% of developing invasive cancer. In these women with double the 5-year risk, 96.2% had a family history of breast cancer and 92.4% had a prior biopsy. Similarly, in women under 60, greater than half were high risk secondary to a prior biopsy or family history. Conclusions: 1/3 of patients who receive annual screening are at high risk for breast cancer. These patients can be identified from data routinely obtained at the time of screening mammography. Many were found to be at increased risk due to a strong family history or prior biopsy. Mammography centers may be the ideal setting in which to alert these patients of their risk and refer them to high risk centers for genetic counseling and consideration of chemoprevention.

scholarly journals Risk of invasive breast cancer in relatives of patients with breast carcinoma in situ: a prospective cohort study

BMC Medicine ◽  
2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Trasias Mukama ◽  
Mahdi Fallah ◽  
Hermann Brenner ◽  
Xing Xu ◽  
Kristina Sundquist ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Breast Carcinoma ◽  
Invasive Breast Cancer ◽  
Carcinoma In Situ ◽  
Degree Relative ◽  
Breast Carcinoma In Situ ◽  
Increased Risk ◽  
History Of

Abstract Background Wide implementation of mammography screening has resulted in increased numbers of women diagnosed with breast carcinoma in situ. We aimed to determine the risk of invasive breast cancer in relatives of patients with breast carcinoma in situ in comparison to the risk in relatives of patients with invasive breast cancer. Methods We analyzed the occurrence of cancer in a nationwide cohort including all 5,099,172 Swedish women born after 1931 with at least one known first-degree relative. This was a record linkage study of Swedish family cancer datasets, including cancer registry data collected from January 1, 1958, to December 31, 2015. We calculated standardized incidence ratios (SIRs) and 10-year cumulative risk of breast cancer diagnosis for women with a family history of in situ and invasive breast cancer. Results Having one first-degree relative with breast carcinoma in situ was associated with 50% increased risk of invasive breast cancer (SIR = 1.5, 95% CI 1.4–1.7) when compared to those who had no family history of invasive breast cancer or breast carcinoma in situ in either first- or second-degree relatives. Similarly, having one first-degree relative with invasive breast cancer was associated with 70% (1.7, 1.7–1.8) increased risk. The 10-year cumulative risk for women at age 50 with a relative with breast carcinoma in situ was 3.5% (2.9–3.9%) and was not significantly different from 3.7% (3.6–3.8%) risk for 50-year-old women with a relative with invasive breast cancer (95% confidence intervals overlapped). Conclusions The risk of invasive breast cancer for women with a family history of breast carcinoma in situ was comparable to that for women with a family history of invasive breast cancer. Therefore, family history of breast carcinoma in situ should not be overlooked in recommendations for breast cancer prevention for women with a family history of breast cancer.

scholarly journals Mammographic microcalcifications and risk of breast cancer

2021 ◽  
Author(s):  
Shadi Azam ◽  
Mikael Eriksson ◽  
Arvid Sjölander ◽  
Marike Gabrielson ◽  
Roxanna Hellgren ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Detection System ◽  
Premenopausal Women ◽  
Computer Aided Detection ◽  
Comprehensive Information ◽  
Estimated Risk ◽  
Logistic Regressions ◽  
Microcalcification Clusters

Abstract Background Mammographic microcalcifications are considered early signs of breast cancer (BC). We examined the association between microcalcification clusters and the risk of overall and subtype-specific BC. Furthermore, we studied how mammographic density (MD) influences the association between microcalcification clusters and BC risk. Methods We used a prospective cohort (n = 53,273) of Swedish women with comprehensive information on BC risk factors and mammograms. The total number of microcalcification clusters and MD were measured using a computer-aided detection system and the STRATUS method, respectively. Cox regressions and logistic regressions were used to analyse the data. Results Overall, 676 women were diagnosed with BC. Women with ≥3 microcalcification clusters had a hazard ratio [HR] of 2.17 (95% confidence interval [CI] = 1.57–3.01) compared to women with no clusters. The estimated risk was more pronounced in premenopausal women (HR = 2.93; 95% CI = 1.67–5.16). For postmenopausal women, microcalcification clusters and MD had a similar influence on BC risk. No interaction was observed between microcalcification clusters and MD. Microcalcification clusters were significantly associated with in situ breast cancer (odds ratio: 2.03; 95% CI = 1.13–3.63). Conclusions Microcalcification clusters are an independent risk factor for BC, with a higher estimated risk in premenopausal women. In postmenopausal women, microcalcification clusters have a similar association with BC as baseline MD.

Sign in / Sign up

Export Citation Format

Share Document